Sub-Sensitivity to Long-Acting Bronchodilators (LABA)
| Condition | Asthma |
|---|---|
| Phase | N/A |
| Sponsor | National Jewish Health |
| Status | Completed |
| Enrollment | 20 participants |
| Interventions | fluticasone propionate and salmeterol, budesonide and formoterol |
| Start date | Mar, 2010 |
| Completion date | Sep, 2013 |
| Results posted | Jul 6, 2026 |
Summary
The purpose of this study is to look at whether Advair® and SYMBICORT® have different effects on airway constriction by means of methacholine challenge testing.
Improvement in PC20
| Fluticasone Propionate and Salmeterol | 0.55 PC20 mg/ml |
|---|---|
| Budesonide and Formoterol | 0.41 PC20 mg/ml |
| Fluticasone Propionate and Salmeterol | 0.64 PC20 mg/ml |
| Budesonide and Formoterol | 0.47 PC20 mg/ml |
Open in BENITIONS View on ClinicalTrials.gov
Other trials for this condition
- A Study of Remote Asthma Management Using an Integrated Artificial Intelligence-assisted E — Mayo Clinic
- Developing a Childhood Asthma Risk Passive Digital Marker — Indiana University
- A Study Testing the Superiority of CHF 1535 pMDI 800/24µg Total Daily Dose Compared With C — Chiesi Farmaceutici S.p.A.
- A Study Evaluating the Efficacy and Safety of Lebrikizumab in Adult Patients With Mild to — Hoffmann-La Roche
- A Study of Lebrikizumab in Participants With Uncontrolled Asthma Who Are on Inhaled Cortic — Hoffmann-La Roche
- Effectiveness and Safety Study of Tezepelumab in Adults & Adolescent Participants With Sev — AstraZeneca